E. William Radany has over 25 years experience in the biotechnology industry. Prior to joining Verdezyne, he was the President and CEO of High Throughput Genomics, Inc., a provider of novel array-based gene expression assay technology for the life science industry. Previously, Dr. Radany was President of Biacore and founder and CEO of NeoGenex. Dr. Radany has held executive positions at Xencor, Caliper Technologies and Stratagene, where he helped establish business relationships with major pharmaceutical and biotechnology companies. Dr. Radany has spoken at numerous conferences and has invented several patents over the past 25 years. Dr. Radany received his Bachelor of Science degree in Cell Biology from Colorado State University and a Ph.D. in Biochemistry/Physiology from the University of Wyoming.

Stephen Picataggio has over 30 years experience in metabolic engineering of industrial microorganisms and developing fermentation processes for the production of fuels and chemicals. Prior to joining Verdezyne, Dr. Picataggio was Vice President of metabolic engineering at Synthetic Genomics, Inc., and held various leadership positions at Dupont, the National Renewable Energy Laboratory and Henkel/Cognis Corp. He was a Postdoctoral Research Associate at the Massachusetts Institute of Technology and is the recipient of several awards as well as an inventor on more than 45 issued and pending patents. Dr. Picataggio received his Bachelor of Science degree in Bacteriology and Public Health from Wagner College and a Ph.D. in Microbiology from Rutgers University.

Brian Conn has served as a financial executive in high growth companies for over twenty years, within and outside of the life sciences industry. Since 2000, Mr. Conn has held executive positions, including Chief Financial Officer with Chemicon International, Serologicals Corporation, Millipore Corporation and MicroIslet Inc. From 1995 to 2000, he was Vice President of Finance and Corporate Controller for Vista Information Solutions, Inc. an internet-based real estate information supplier. From 1988 to 1995, Mr. Conn served various financial and executive roles in healthcare and real estate companies. He has extensive experience with capital transactions, mergers and acquisitions and ERP implementations. Mr. Conn holds a BS in Finance from Arizona State University.

Nancy Oleski has been practicing law in the biotechnology industry for more than 17 years. Prior to working at Verdezyne, Dr. Oleski was Vice President for Codexis, Inc., where she was responsible for developing and implementing a worldwide strategy for all intellectual property matters for platform technologies and for each of its business units including biofuels/bioindustrials, pharmaceutical services and generic drugs. Prior to joining Codexis, Inc., Dr. Oleski held positions at Nuvelo, Inc. and Amgen, Inc. Dr. Oleski began her career as a patent agent at Genentech Inc. followed by the law firm of Townsend and Townsend. Dr. Oleski received her Bachelor of Arts degree in Biology from Scripps College, Master of Science in Plant Physiology from Colorado State University, Ph.D. in Plant Biochemistry from the University of California and her J.D. from the Golden Gate University School of Law.